Mineralys Therapeutics, Inc. (MLYS): who owns it and who trades it
As of Nov 16, 2026, MLYS insiders reported 58 open-market sales worth $71.3M and 2 purchases worth $8.8M in the last 12 months, with 35% of the sale value made under pre-set 10b5-1 plans. The largest seller was Catalys Pacific Fund, LP (10% owner), with $43.4M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Mineralys Therapeutics
From the latest filingsOverall: about as much buying as selling. Famous investors mostly sold. Funds and insiders were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns MLYS
226 funds and institutions reported MLYS shares worth $2.8B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Catalys Pacific, LLC with 9.6%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Catalys Pacific, LLC | 7.90M | 9.59% | $213M | No change |
| Ra Capital Management, L.P. | 7.69M | 9.34% | $208M | No change |
| BlackRock, Inc. | 5.89M | 7.14% | $159M | +31% |
| Samsara Biocapital, LLC | 5.87M | 7.13% | $158M | No change |
| FMR LLC (Fidelity) | 4.51M | 5.48% | $122M | -7% |
| State Street Corp | 4.14M | 5.03% | $112M | +41% |
| Deerfield Management Company, L.P. | 3.96M | 4.80% | $107M | – |
| Vanguard Capital Management LLC | 2.76M | 3.35% | $74.4M | +12% |
| Laurion Capital Management LP | 2.51M | 3.04% | $67.6M | +12% |
| T. Rowe Price Associates | 2.26M | 2.75% | $61M | +68% |
| Orbimed Advisors LLC | 2.11M | 2.56% | $56.9M | +3% |
| Capital World Investors | 2.00M | 2.42% | $53.9M | +402% |
| California State Teachers Retirement System | 1.81M | 2.20% | $67.2M | +2860% |
| Armistice Capital, LLC | 1.74M | 2.11% | $46.8M | +48% |
| Troluce Capital Advisors LLC | 1.73M | 2.10% | $46.6M | +164% |
| Nantahala Capital Management, LLC | 1.64M | 1.99% | $44.3M | +83% |
| Franklin Resources Inc | 1.64M | 1.98% | $44.1M | -8% |
| Andera Partners | 1.59M | 1.93% | $42.9M | No change |
| Geode Capital Management, LLC | 1.58M | 1.92% | $42.8M | +22% |
| SR One Capital Management, LP | 1.56M | 1.90% | $42.2M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, MLYS insiders reported $8.8M of open-market purchases and $71.3M of sales. 35% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Jon Congleton | CEO | Sale plan | 75,000 | $25.46 | $1.9M | Form 4 |
| Sep 22, 2026 | Brian Taylor Slingsby | Director | Sale | 104,320 | $28.81 | $3M | Form 4 |
| Sep 21, 2026 | Eric Warren | Chief Commercial Officer | Sale plan | 7,438 | $28.12 | $209K | Form 4 |
| Sep 15, 2026 | Daphne Karydas | Director | Sale plan | 3,000 | $28.58 | $85.7K | Form 4 |
| Aug 21, 2026 | Eric Warren | Chief Commercial Officer | Sale plan | 7,437 | $25.98 | $193K | Form 4 |
| Aug 10, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 2,170 | $27.09 | $58.8K | Form 4 |
| Jul 21, 2026 | Eric Warren | Chief Commercial Officer | Sale plan | 7,438 | $26.87 | $200K | Form 4 |
| Jul 17, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 416 | $26.53 | $11K | Form 4 |
| Jul 15, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 6,349 | $26.61 | $169K | Form 4 |
| Jul 13, 2026 | Jon Congleton | CEO | Sale plan | 10,700 | $27.24 | $291K | Form 4 |
| Jul 13, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 14,058 | $27.58 | $388K | Form 4 |
| Jul 9, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 2,171 | $30.30 | $65.8K | Form 4 |
| Jun 30, 2026 | Jon Congleton | CEO | Sale plan | 17,000 | $26.82 | $456K | Form 4 |
| Jun 30, 2026 | Jon Congleton | CEO | Sale plan | 58,000 | $25.94 | $1.5M | Form 4 |
| Jun 26, 2026 | Eric Warren | Chief Commercial Officer | Sale plan | 104,124 | $25.90 | $2.7M | Form 4 |
| Jun 17, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 4,584 | $25.00 | $115K | Form 4 |
| Jun 17, 2026 | Daphne Karydas | Director | Sale plan | 3,000 | $25.00 | $75K | Form 4 |
| Jun 15, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 9,890 | $23.81 | $235K | Form 4 |
| Jun 12, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 6,349 | $23.93 | $152K | Form 4 |
| Jun 10, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 2,170 | $25.00 | $54.2K | Form 4 |
| May 18, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 417 | $27.55 | $11.5K | Form 4 |
| May 13, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 14,056 | $28.58 | $402K | Form 4 |
| May 12, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 6,348 | $29.36 | $186K | Form 4 |
| May 11, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 2,171 | $29.71 | $64.5K | Form 4 |
| Apr 17, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 416 | $31.33 | $13K | Form 4 |
| Apr 15, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 6,348 | $27.66 | $176K | Form 4 |
| Apr 13, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 14,058 | $26.54 | $373K | Form 4 |
| Apr 13, 2026 | Jon Congleton | CEO | Sale plan | 15,730 | $26.83 | $422K | Form 4 |
| Apr 9, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 2,170 | $27.38 | $59.4K | Form 4 |
| Mar 31, 2026 | Jon Congleton | CEO | Sale plan | 19,364 | $25.50 | $494K | Form 4 |
| Mar 31, 2026 | Jon Congleton | CEO | Sale plan | 453 | $27.05 | $12.3K | Form 4 |
| Mar 31, 2026 | Jon Congleton | CEO | Sale plan | 55,183 | $26.54 | $1.5M | Form 4 |
| Mar 31, 2026 | Daphne Karydas | Director | Sale plan | 3,000 | $25.00 | $75K | Form 4 |
| Mar 30, 2026 | Rajeev M. Shah +4 | Director | Purchase | 58,300 | $24.16 | $1.4M | Form 4 |
| Mar 27, 2026 | Rajeev M. Shah +4 | Director | Purchase | 310,700 | $23.67 | $7.4M | Form 4 |
| Mar 17, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 417 | $25.65 | $10.7K | Form 4 |
| Mar 13, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 253 | $27.82 | $7K | Form 4 |
| Mar 13, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 10,726 | $25.91 | $278K | Form 4 |
| Mar 13, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 3,079 | $27.37 | $84.3K | Form 4 |
| Mar 12, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 6,348 | $27.37 | $174K | Form 4 |
| Mar 9, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 2,171 | $26.84 | $58.3K | Form 4 |
| Feb 17, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 417 | $27.59 | $11.5K | Form 4 |
| Feb 13, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 4,166 | $27.33 | $114K | Form 4 |
| Feb 13, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 6,348 | $27.58 | $175K | Form 4 |
| Feb 13, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 3,541 | $27.33 | $96.8K | Form 4 |
| Feb 12, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 521 | $29.64 | $15.4K | Form 4 |
| Feb 12, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 5,828 | $28.94 | $169K | Form 4 |
| Feb 9, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 2,171 | $30.21 | $65.6K | Form 4 |
| Jan 20, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 416 | $32.10 | $13.4K | Form 4 |
| Jan 14, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 11,367 | $32.61 | $371K | Form 4 |
| Jan 13, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 7,709 | $32.75 | $252K | Form 4 |
| Jan 12, 2026 | Jon Congleton | CEO | Sale plan | 9,119 | $32.21 | $294K | Form 4 |
| Jan 12, 2026 | Jon Congleton | CEO | Sale plan | 7,117 | $33.15 | $236K | Form 4 |
| Jan 12, 2026 | Adam Scott Levy | CFO | Sale plan | 10,758 | $32.14 | $346K | Form 4 |
| Jan 12, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 6,348 | $32.32 | $205K | Form 4 |
| Jan 9, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 2,170 | $33.27 | $72.2K | Form 4 |
| Jan 5, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 53,470 | $35.53 | $1.9M | Form 4 |
| Jan 5, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 139,245 | $34.83 | $4.8M | Form 4 |
| Jan 2, 2026 | David Malcom Rodman | Chief Medical Officer | Sale plan | 70,037 | $35.87 | $2.5M | Form 4 |
| Nov 20, 2025 | Catalys Pacific Fund, LP +1 | 10% owner | Sale | 1.00M | $43.35 | $43.4M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Catalys Pacific Fund, LP | 10% owner | – | $43.4M | Nov 20, 2025 |
| David Malcom Rodman | Chief Medical Officer | – | $14M | Aug 10, 2026 |
| Rajeev M. Shah | Director | $8.8M | – | Mar 30, 2026 |
| Jon Congleton | Chief Executive Officer, Director | – | $7.1M | Sep 30, 2026 |
| Eric Warren | Chief Commercial Officer | – | $3.3M | Sep 21, 2026 |
| Brian Taylor Slingsby | Director | – | $3M | Sep 22, 2026 |
| Adam Scott Levy | CFO and Secretary | – | $346K | Jan 12, 2026 |
| Daphne Karydas | Director | – | $236K | Sep 15, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MLYS short interest
Moderate short interest. 8.7% of MLYS shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 15%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 7.69M MLYS shares were sold short, 8.7% of the shares outstanding, up 3.3% from the report before. At the average daily volume of 1.55M shares, buying them all back would take about 5.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 7.69M | 8.68% | +3% | 1.55M | 5.0 |
| Oct 15, 2026 | 7.44M | 8.41% | -5% | 1.40M | 5.3 |
| Sep 30, 2026 | 7.81M | 8.83% | -15% | 1.51M | 5.2 |
| Sep 15, 2026 | 9.18M | 10.39% | -2% | 1.44M | 6.4 |
| Aug 31, 2026 | 9.33M | 10.56% | -3% | 818,574 | 11.4 |
| Aug 14, 2026 | 9.65M | 10.91% | +4% | 744,755 | 12.9 |
| Jul 31, 2026 | 9.31M | 11.30% | -3% | 618,178 | 15.1 |
| Jul 15, 2026 | 9.55M | 11.59% | -14% | 976,498 | 9.8 |
| Jun 30, 2026 | 11.10M | 13.47% | +28% | 2.12M | 5.2 |
| Jun 15, 2026 | 8.70M | 10.56% | -8% | 2.48M | 3.5 |
| May 29, 2026 | 9.48M | 11.50% | +5% | 1.39M | 6.8 |
| May 15, 2026 | 9.02M | 10.95% | +6% | 1.10M | 8.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Mineralys Therapeutics company events
Mineralys Therapeutics filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026LeadershipDerek DiRocco, Ph.D. informed the Board of Directors (the Board) of the Company of his decision to resign from the Board, effective as of December 31, 2026. Filing
- Oct 29, 2026AgreementMineralys Therapeutics, Inc. (the Company) and Tanabe Pharma Corporation (Tanabe) were previously parties to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023, May 29, 2025 and June 2, 2026 (as amended, the License Agreement), pursuant to which… Filing
- Oct 19, 2026LeadershipThe Board of Directors (the Board) of Mineralys Therapeutics, Inc. (the Company) appointed Kristine Peterson and Lonnel Coats to the Board effective as of October 19, 2026, increasing the size of the Board from seven to nine directors. Filing
- Aug 11, 2026LeadershipThe Company’s Board of Directors (the Board) appointed James J. Ferguson III, M.D., as the Company’s new Chief Medical Officer, effective August 10, 2026, replacing David Rodman, M.D., who remains with the Company on a full-time basis as a Strategic Advisor. Filing
- Jun 3, 2026AnnouncementMineralys Therapeutics, Inc. entered into an underwriting agreement with BofA Securities, Inc., Goldman Sachs & Co. LLC and Evercore Group L.L.C., relating to the issuance and sale of 5,660,378 shares of the Company’s common stock, par value $0.0001 per share. Filing
- Jun 3, 2026AgreementMineralys Therapeutics, Inc. entered into a fourth amendment to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023 and May 29, 2025, between the Company and Tanabe Pharma Corporation for the purposes of terminating the Company’s potential future… Filing
- May 22, 2026VoteReported shareholder vote results. Filing
- May 6, 2026ResultsReleased financial results. Filing
- Mar 12, 2026ResultsReleased financial results. Filing
- Mar 9, 2026AnnouncementThe FDA notified the Company that its NDA for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs had been accepted. Filing
- Jan 6, 2026AnnouncementThe Company issued a press release disclosing that it (i) filed a new drug application for lorundrostat to the U.S. Food and Drug Administration in late 2025 and (ii) remains on track to report topline results from its Phase 2 Explore-OSA trial, which is evaluating the safety and efficacy of… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Mineralys Therapeutics financials
Famous investors that hold MLYS
5 of the 50 well-known investors we track reported holding MLYS in their latest 13F filing. The largest position is Steve Cohen's, worth $31.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.27M | $31.9M | 0.1% | New |
| Israel Englander · Millennium Management | Q3 2026 | 708,360 | $17.8M | 0.0% | -42% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 417,131 | $10.5M | 0.0% | +10% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 263,276 | $6.6M | 0.0% | -44% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 56,743 | $1.4M | 0.0% | -92% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Mineralys Therapeutics, Inc. (MLYS) stock
Who owns the most MLYS stock?
The largest reported owner of Mineralys Therapeutics, Inc. (MLYS) is Catalys Pacific, LLC, with 9.6% of the company. In total, 226 funds and institutions reported holding MLYS at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are MLYS insiders buying or selling?
In the last 12 months, MLYS insiders reported 2 open-market purchases worth $8.8M and 58 sales worth $71.3M. The latest trade was on Sep 30, 2026. See every trade.
What is the short interest in MLYS?
As of Oct 30, 2026, 7.69M MLYS shares were sold short, 8.7% of the shares outstanding, up 3.3% from the report before. At the average daily volume of 1.55M shares, buying them all back would take about 5.0 trading days (days to cover). See the history.
Which famous investors hold MLYS?
5 of the 50 well-known investors we track reported MLYS in their latest 13F filing, including Steve Cohen, Israel Englander, Jim Simons. The largest position is worth $31.9M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.